BI 765423 and Standard of Care for Idiopathic Pulmonary Fibrosis

This study is focused on adults aged 40 and older who have idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring and affects breathing. To join, participants must have a specific lung capacity and a certain amount of lung scarring confirmed by a detailed scan. The aim is to see if a new medicine, BI 765423, can help improve lung function in these individuals. The study is important because it hopes to find better treatment options for IPF, a condition with limited therapies currently available, potentially helping those affected to breathe easier and improve their quality of life. Participants are randomly assigned to receive either the BI 765423 medicine or a placebo, which looks like the medicine but has no active ingredients, through a vein infusion every four weeks. They remain in the study for 8 to 10 months, during which they can continue their usual IPF treatments. Throughout the study, participants visit the study site for various tests, including lung function assessments and blood samples, to monitor health and effectiveness of the treatment. Doctors compare results from both groups to determine if the new medicine shows better outcomes and check for any side effects.